Gene therapy and biotechnology research by Regenxbio
Global MPS researchers collaborate as REGENXBIO strengthens commitment to lysosomal disease progress
REGENXBIO participated in the international gathering of the MPS community in Florence, engaging with International MPS Network members and attending the International Symposium on MPS and Related ...
REGENXBIO reports positive topline pivotal data for RGX-202 in Duchenne study
REGENXBIO announced positive topline pivotal data from its RGX-202 program for Duchenne muscular dystrophy. The company highlighted its participation at the FUTURES National Conference, hosted ...
Gene therapy innovation gains momentum at REGENXBIO during ASGCTherapy event
REGENXBIO participated in the ASGCTherapy Annual Meeting, engaging with attendees and underscoring its commitment to advancing the field of gene therapy. The company thanked collaborators and ...
REGENXBIO credits administrative team for ongoing operational success
REGENXBIO has acknowledged the critical contributions of its administrative team, commending their expertise and execution in keeping company operations running smoothly. In a statement, the ...
REGENXBIO prioritizes patient access by strengthening commercial leadership
REGENXBIO is stepping up its commercial operations with the active involvement of Paul Oyefesobi on its commercial team. Oyefesobi is playing a central role in ensuring that the company is ...
REGENXBIO joins CureDuchenne community event to advance therapies for Duchenne
REGENXBIO participated in a weekend event hosted by CureDuchenne, bringing together families, patients, and researchers for a day dedicated to learning and building connections. The gathering ...
Patient centric approach drives AFFINITY DUCHENNE study expansion at REGENXBIO
REGENXBIO has reiterated its commitment to placing patients and families at the forefront of its initiatives, focusing on the ongoing AFFINITY DUCHENNE study. Vanessa Jimenez, Associate Director ...
REGENXBIO commends women leadership driving mission on International Womens Day
REGENXBIO recognized the significant contributions of women within its organization on International Womens Day. The company credited its progress toward delivering impactful change for patients ...
Team powers gene therapy mission, REGENXBIO asserts
REGENXBIO recognized its workforce on Employee Appreciation Day, commending the passion and dedication driving its mission to deliver gene therapy solutions for patients and families in need. The ...
REGENXBIO to present new RGX-202 clinical data at 2026 MDA Clinical and Scientific Conference
REGENXBIO has announced plans to deliver new clinical data from the Phase I/II AFFINITY DUCHENNE trial of RGX-202 at the 2026 Muscular Dystrophy Association (MDA) Clinical and Scientific ...
REGENXBIO to announce Q4 and full year 2025 results in March conference call
REGENXBIO will host a conference call on March 5 to present its fourth quarter and full year 2025 financial results and operational highlights. The company is set to provide shareholders and ...
Regenxbio highlights 56 percent women workforce on International Day of Women and Girls in Science
Regenxbio has announced that women constitute 56 percent of their workforce, highlighting their essential role within the company on International Day of Women and Girls in Science. These women ...
REGENXBIO advances gene therapies for diabetic retinopathy
REGENXBIO is focusing efforts on developing gene therapies to address diabetic retinopathy, a complication faced by up to 25% of individuals with diabetes. This condition is a leading cause of ...
REGENXBIO drives momentum in biopharma ecosystem discussions
REGENXBIO announced that its Chief Commercial Officer, Ram Palanki, PharmD, will be participating in discussions hosted by Longwood Leaders. This event will focus on addressing significant ...
